SCHEMBL23780407

SCHEMBL23780407

Cc1nc(-c2ccc(CNc3ccc(C#N)cn3)cc2)no1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 9/20 0.50
HDAC1 Q13547 7/20 0.47
HDAC4 P56524 4/20 0.47
EP300 Q09472 1/20 0.45
HDAC8 Q9BY41 4/20 0.44
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C9 P11712 1/20 0.43
HPGD P15428 1/20 0.43
CYP2C19 P33261 1/20 0.43
IDH1 O75874 1/20 0.43
CTSL P07711 1/20 0.42
CTSB P07858 1/20 0.42
CTSS P25774 1/20 0.42
CTSK P43235 1/20 0.42
DYRK1A Q13627 1/20 0.42
CLK4 Q9HAZ1 1/20 0.42
GSK3B P49841 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30172415 0.84 HDAC6 (0.45) HDAC6HDAC1HDAC4HDAC8KDM4E
SCHEMBL23780444 0.84 HDAC6 (0.45) HDAC6HDAC1HDAC4HDAC8KDM4E
SCHEMBL23780463 0.84 CLK4 (0.52) HDAC6HDAC1HDAC8KDM4EALDH1A1
SCHEMBL23780406 0.82 HDAC6 (0.50) HDAC6HDAC1HDAC4HDAC8KDM4E
SCHEMBL23780460 0.81 HDAC6 (0.42) HDAC6HDAC1HDAC4HDAC8KDM4E
SCHEMBL23780424 0.79 HDAC6 (0.49) HDAC6HDAC1HDAC4HDAC8ALDH1A1
SCHEMBL23780452 0.78 HDAC6 (0.47) HDAC6HDAC1HDAC4HDAC8CTSL
SCHEMBL30172454 0.78 HDAC6 (0.47) HDAC6HDAC1HDAC4HDAC8CTSL
SCHEMBL22629501 0.77 L3MBTL1 (0.53) HDAC6EP300ALDH1A1HPGD
SCHEMBL23291999 0.76 MPO (0.44) HDAC6HDAC1HDAC4HDAC8KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12187712-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2025-01-07 US claimed
EP-3814343-B1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS INC (US) 2023-01-11 EP claimed
US-12187712-B2 Cardiac sarcomere inhibitors CYTOKINETICS, INC. (US) 2025-01-07 US disclosed
EP-3814343-B1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS INC (US) 2023-01-11 EP disclosed
US-20210276991-A1 CARDIAC SARCOMERE INHIBITORS CYTOKINETICS, INC. 2021-09-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12187712-B2 Cardiac sarcomere inhibitors TNNI3, TNNT2, MYLK2 HDAC6 233/4885HDAC1 203/4885HDAC4 771/4885
US-20210276991-A1 CARDIAC SARCOMERE INHIBITORS TNNI3, TNNT2, MYLK2 HDAC6 233/4885HDAC1 203/4885HDAC4 771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.